| Literature DB >> 22814612 |
Xueting Liu1, Caixia Chen, Wenni He, Pei Huang, Miaomiao Liu, Qian Wang, Hui Guo, Krishna Bolla, Yan Lu, Fuhang Song, Huanqin Dai, Mei Liu, Lixin Zhang.
Abstract
Multidrug-resistant tuberculosis (MDR-TB) and TB-HIV co-infection have become a great threat to global health. However, the last truly novel drug that was approved for the treatment of TB was discovered 40 years ago. The search for new effective drugs against TB has never been more intensive. Natural products derived from microbes and medicinal plants have been an important source of TB therapeutics. Recent advances have been made to accelerate the discovery rate of novel TB drugs including diversifying strategies for environmental strains, high-throughput screening (HTS) assays, and chemical diversity. This review will discuss the challenges of finding novel natural products with anti-TB activity from marine microbes and plant medicines, including biodiversity- and taxonomy-guided microbial natural products library construction, target- and cell-based HTS, and bioassay-directed isolation of anti-TB substances from traditional medicines.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22814612 DOI： 10.1007/s10482-012-9777-0
Source DB: PubMed Journal: Antonie Van Leeuwenhoek ISSN： 0003-6072 Impact factor: 2.271